National Committee for Quality Assurance ► Annual monitoring for patients on persistent medications

NQMC Update Service: September 24, 2012

National Committee for Quality Assurance

• Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of ACE inhibitors or ARBs during the measurement year and had at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. This updates a previously published measure summary.

• Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of anticonvulsants during the measurement year and had at least one drug serum concentration level monitoring test for the prescribed drug in the measurement year. This updates a previously published measure summary.

• Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of digoxin during the measurement year and had at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. This updates a previously published measure summary.

• Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of diuretics during the measurement year and had at least one serum potassium and either a serum creatinine or a blood urea nitrogen therapeutic monitoring test in the measurement year. This updates a previously published measure summary.

• Medication reconciliation post-discharge: percentage of discharges from January 1 to December 1 of the measurement year for members 66 years of age and older for whom medications were reconciled on or within 30 days of discharge. This updates a previously published measure summary.

• Potentially harmful drug-disease interactions in the elderly: percentage of Medicare members 65 years of age and older who have a diagnosis of CRF and a prescription for nonaspirin NSAIDs or Cox-2 selective NSAIDs. This updates a previously published measure summary.

• Potentially harmful drug-disease interactions in the elderly: percentage of Medicare members 65 years of age and older who have a diagnosis of dementia and a prescription for tricyclic antidepressants or anticholinergic agents. This updates a previously published measure summary.

• Potentially harmful drug-disease interactions in the elderly: percentage of Medicare members 65 years of age and older who have a history of falls and a prescription for tricyclic antidepressants, antipsychotics or sleep agents. This updates a previously published measure summary.

• Use of high-risk medications in the elderly: percentage of Medicare members 65 years of age and older who received at least one high-risk medication. This updates a previously published measure summary.

• Use of high-risk medications in the elderly: percentage of Medicare members 65 years of age and older who received at least two different high-risk medications. This updates a previously published measure summary.